-
Je něco špatně v tomto záznamu ?
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
O. Fiala, J. Finek, A. Poprach, B. Melichar, J. Kopecký, M. Zemanova, K. Kopeckova, T. Mlcoch, T. Dolezal, L. Capkova, T. Buchler,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
National Sustainability Program I (NPU I) Nr. LO1503
undefined <span style="color:gray;font-size:10px;">undefined</span>
LO1503
Ministerstvo Školství, Mládeže a Tělovýchovy
Progres Q39
Univerzita Karlova v Praze
CZ.02.1.01/0.0/0.0/17_048/0007280
European Regional Development Fund
NV19-08-00250
Ministerstvo Zdravotnictví Ceské Republiky
Nº856620
Horizon 2020
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
32230921
DOI
10.3390/cancers12040808
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. METHODS: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. RESULTS: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). CONCLUSIONS: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019414
- 003
- CZ-PrNML
- 005
- 20201123123341.0
- 007
- ta
- 008
- 201103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers12040808 $2 doi
- 035 __
- $a (PubMed)32230921
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, 304 60 Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 304 60 Pilsen, Czech Republic.
- 245 10
- $a Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients / $c O. Fiala, J. Finek, A. Poprach, B. Melichar, J. Kopecký, M. Zemanova, K. Kopeckova, T. Mlcoch, T. Dolezal, L. Capkova, T. Buchler,
- 520 9_
- $a BACKGROUND: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. METHODS: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. RESULTS: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). CONCLUSIONS: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, 304 60 Pilsen, Czech Republic.
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Kopecký, Jindrich $u Department of Oncology, University Hospital in Hradec Králové, Sokolská 581, 50005 Hradec Králové, Czech Republic.
- 700 1_
- $a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 08 Prague, Czech Republic.
- 700 1_
- $a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic.
- 700 1_
- $a Mlcoch, Tomas $u Institute of Health Economics and Technology Assessment (iHETA), Vaclavska 316/12, 120 00 Prague, Czech Republic.
- 700 1_
- $a Dolezal, Tomas $u Institute of Health Economics and Technology Assessment (iHETA), Vaclavska 316/12, 120 00 Prague, Czech Republic. Faculty of Medicine, Masaryk University, Department of Pharmacology, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Capkova, Lenka $u Institute of Biostatistics and Analyses, Ltd., Poštovská 68/3, 602 00 Brno, Czech Republic.
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59 Prague, Czech Republic.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 4 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32230921 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123123340 $b ABA008
- 999 __
- $a ind $b bmc $g 1586191 $s 1109612
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 12 $c 4 $e 20200327 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a National Sustainability Program I (NPU I) Nr. LO1503 $p undefined <span style="color:gray;font-size:10px;">undefined</span>
- GRA __
- $a LO1503 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a Progres Q39 $p Univerzita Karlova v Praze
- GRA __
- $a CZ.02.1.01/0.0/0.0/17_048/0007280 $p European Regional Development Fund
- GRA __
- $a NV19-08-00250 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a Nº856620 $p Horizon 2020
- LZP __
- $a Pubmed-20201103
